Arteriovenous malformations market seen reaching $4.37B by 2030

The arteriovenous malformations market is projected to grow from $3.1 billion in 2025 to $4.37 billion by 2030, driven by minimally invasive treatment adoption, better diagnostics and rising biotech investment. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - The arteriovenous malformations market is moving from a niche segment into a faster-growing specialty care category. - Better imaging, more precise procedures and broader biotech investment are expanding treatment options for patients with AVMs. - The market forecast points to sustained demand for minimally invasive care and advanced interventional devices through 2030.

What happened: - The Business Research Company released its 2026 global market report on arteriovenous malformations. - The report says the market will grow from $3.1 billion in 2025 to $3.33 billion in 2026. - The report projects the market will reach $4.37 billion by 2030. - The forecast implies a 7.3% CAGR from 2025 to 2026 and a 7.1% CAGR through 2030. - The report was published Nov. 2, 2026, in London. - A free sample of the report is available. - The company also offered the full market report.

The details: - Arteriovenous malformations are abnormal clusters of blood vessels that create direct connections between arteries and veins. - AVMs bypass the capillary network, disrupting normal blood flow and oxygen delivery. - Untreated AVMs can lead to serious health complications. - Early detection and treatment are critical to reducing symptoms and lowering the risk of severe outcomes. - The report ties recent growth to better neuroimaging, stronger clinical awareness and more specialized neurosurgical centers. - Wider use of endovascular embolization and more hospital-based neurological care also supported the market. - Future growth is expected to come from demand for precise diagnostics, more funding for neurovascular research and greater use of personalized therapy plans. - The report also points to broader access to advanced interventional devices. - Minimally invasive procedures are a key growth driver because they reduce tissue trauma, recovery time and complication rates versus open surgery. - AVM care has benefited from catheter-based endovascular embolization guided by imaging. - In September 2023, the American Society of Plastic Surgeons reported 25,442,640 cosmetic minimally invasive procedures in the U.S., up from 23,672,269 in 2022. - That 7% increase is cited as evidence of wider acceptance of less invasive medical interventions. - Biotechnology investment is another driver because it supports new tools for imaging, gene therapy and targeted delivery. - The report highlights CRISPR, biomaterials, and AI-assisted diagnostic tools as enabling technologies. - In August 2024, the BioIndustry Association said the UK life sciences and biotechnology sector drew $2.55 billion in first-half 2024 investment. - That total exceeded the $2.32 billion raised in all of 2023.

Between the lines: - The market story is less about AVMs alone and more about a broader shift toward precision medicine and less invasive intervention. - The reported growth rate suggests buyers and providers are investing in tools that can diagnose sooner and treat with fewer complications. - The emphasis on biotech funding signals that innovation in AVM care may come from adjacent advances, not just neurosurgery.

What's next: - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company says its 2026 reports add market attractiveness scoring, TAM analysis, company scoring matrix graphics and Excel-based forecasting dashboards. - The report also includes market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.